P A Coffie1, A Patassi2, A Doumbia3, G Bado4, E Messou5, A Minga6, E Allah-Kouadio7, D M Zannou8, M Seydi9, A R Kakou3, F Dabis10, G Wandeler11. 1. Département de dermatologie et d'infectiologie, UFR des sciences médicales, université Félix-Houphouët Boigny, Abidjan, Cote d'Ivoire; Service des maladies infectieuses et tropicales, centre hospitalier universitaire de Treichville, Abidjan, Cote d'Ivoire; Programme PACCI, site ANRS Côte d'Ivoire, Abidjan, Cote d'Ivoire. Electronic address: ahuatchi@gmail.com. 2. Service des maladies infectieuses et de pneumologie, CHU Sylvanus-Olympio, Lomé, Togo. 3. Département de dermatologie et d'infectiologie, UFR des sciences médicales, université Félix-Houphouët Boigny, Abidjan, Cote d'Ivoire; Service des maladies infectieuses et tropicales, centre hospitalier universitaire de Treichville, Abidjan, Cote d'Ivoire. 4. Service des maladies infectieuses et tropicales, hôpital de Jour, CHU Souro Sanou, Bobo Dioulasso, Burkina-Faso. 5. Département de dermatologie et d'infectiologie, UFR des sciences médicales, université Félix-Houphouët Boigny, Abidjan, Cote d'Ivoire; Service des maladies infectieuses et tropicales, centre hospitalier universitaire de Treichville, Abidjan, Cote d'Ivoire; Centre de prise en charge de recherche et de formation, CePReF-Aconda-VS, Cote d'Ivoire. 6. Centre médical de suivi de donneurs de sang/CNTS/PRIMO-CI, Abidjan, Cote d'Ivoire. 7. Département d'hépato-gastro-entérologie, université Félix-Houphouët Boigny, Abidjan, Cote d'Ivoire. 8. Service de médecine interne, CNHU Hubert-Maga, Cotonou, Benin. 9. Service des maladies infectieuses et tropicales, CHU de Fann, Dakar, Senegal. 10. ISPED, centre Inserm U1219-Bordeaux Population Health, université de Bordeaux, Bordeaux, France. 11. Service des maladies infectieuses et tropicales, CHU de Fann, Dakar, Senegal; Département des maladies infectieuses et institut de médecine sociale et préventive, université de Berne, Berne, Switzerland.
Abstract
BACKGROUND: We aimed to describe changes in hepatitis B screening practices over a 3-year period among HIV-infected patients in West Africa. METHODS: A medical chart review was conducted in urban HIV treatment centers in Ivory Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who started antiretroviral treatment between 2010 and 2012, 100 per year were randomly selected from each clinic. Demographic, clinical, and laboratory data was collected using a standardized questionnaire. We assessed changes in the proportion of patients screened over time and identified predictors of screening in a multivariable logistic regression. RESULTS: A total of 2097 patients were included (median age: 37 years, 65.4% of women). Overall, 313 (14.9%) patients had been screened for hepatitis B, with an increase from 10.6% in 2010 to 18.9% in 2012 (P<0.001) and substantial differences across countries. In multivariable analysis, being aged over 45 years (adjusted odds ratio: 1.34 [1.01-1.77]) and having an income-generating activity (adjusted odds ratio: 1.82 [1.09-3.03]) were associated with screening for hepatitis B infection. Overall, 62 HIV-infected patients (19.8%, 95% confidence interval: 15.5-24.7) were HBsAg-positive and 82.3% of them received a tenofovir-containing drug regimen. CONCLUSION: Hepatitis B screening among HIV-infected patients was low between 2010 and 2012. The increasing availability of HBsAg rapid tests and tenofovir in first-line antiretroviral regimen should improve the rates of hepatitis B screening.
BACKGROUND: We aimed to describe changes in hepatitis B screening practices over a 3-year period among HIV-infectedpatients in West Africa. METHODS: A medical chart review was conducted in urban HIV treatment centers in Ivory Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who started antiretroviral treatment between 2010 and 2012, 100 per year were randomly selected from each clinic. Demographic, clinical, and laboratory data was collected using a standardized questionnaire. We assessed changes in the proportion of patients screened over time and identified predictors of screening in a multivariable logistic regression. RESULTS: A total of 2097 patients were included (median age: 37 years, 65.4% of women). Overall, 313 (14.9%) patients had been screened for hepatitis B, with an increase from 10.6% in 2010 to 18.9% in 2012 (P<0.001) and substantial differences across countries. In multivariable analysis, being aged over 45 years (adjusted odds ratio: 1.34 [1.01-1.77]) and having an income-generating activity (adjusted odds ratio: 1.82 [1.09-3.03]) were associated with screening for hepatitis B infection. Overall, 62 HIV-infectedpatients (19.8%, 95% confidence interval: 15.5-24.7) were HBsAg-positive and 82.3% of them received a tenofovir-containing drug regimen. CONCLUSION:Hepatitis B screening among HIV-infectedpatients was low between 2010 and 2012. The increasing availability of HBsAg rapid tests and tenofovir in first-line antiretroviral regimen should improve the rates of hepatitis B screening.
Authors: Alana T Brennan; Jacob Bor; Mary-Ann Davies; Gilles Wandeler; Hans Prozesky; Geoffrey Fatti; Robin Wood; Kathryn Stinson; Frank Tanser; Till Bärnighausen; Andrew Boulle; Izukanji Sikazwe; Arianna Zanolini; Matthew P Fox Journal: Am J Epidemiol Date: 2018-09-01 Impact factor: 5.363